Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat-Reference-Cited by-同舟云学术

Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat

Published:2016-09 Issue:3 Volume:138 Page:934-936.e5
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Aygören-Pürsün Emel,Magerl Markus,Graff Jochen,Martinez-Saguer Inmaculada,Kreuz Wolfhart,Longhurst Hilary,Nasr Iman,Bas Murat,Straßen Ulrich,Fang Lei,Cornpropst Melanie,Dobo Sylvia,Collis Phil,Sheridan William P.,Maurer Marcus

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference11 articles.

1. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C' 1-esterase;Donaldson;Am J Med,1963

2. Hereditary angio-oedema in Denmark: a nationwide survey;Bygum;Br J Dermatol,2009

3. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency;Bork;J Allergy Clin Immunol,2012

4. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin;Fields;J Allergy Clin Immunol,1983

5. Plasma bradykinin in angio-oedema;Nussberger;Lancet,1998

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19);PHARMAZIE;2023

2. Interventions for the long-term prevention of hereditary angioedema attacks;Cochrane Database of Systematic Reviews;2022-11-03

3. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update;World Allergy Organization Journal;2022-03

4. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update;Allergy;2022-02-03

5. Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity;Chinese Chemical Letters;2021-11